Several Alzheimer's blood tests are in the works – and one is already being sold to consumers – but none have been established as accurate, formally approved by regulators or reimbursed by insurers.
Researchers have been working for years on blood tests for Alzheimer's that can replicate these diagnostic tools.
The need for blood tests has become more pressing since the FDA approved Leqembi in July.
Accurate blood tests are expected to help identify which dementia patients actually have Alzheimer’s, the most common but not the only cause of dementia.
"When there are widely available, scalable, sensitive and specific blood tests it will be an absolute game changer for Alzheimer's patients."
Persons:
Denis Balibouse, Eli Lilly, Dr, Sarah Kremen, Eliezer Masliah, Eisai, Michael Irizarry, Roche, Bruce Jordan, Russ Paulsen, Deena Beasley, Caroline Humer, Bill Berkrot
Organizations:
Memory Centre, of Readaptation, University Hospital, REUTERS, FDA, Sinai Medical Center, Wednesday, Quest Diagnostics, National Institute, Aging, U.S . National Institutes of Health, C2N Diagnostics, Roche Diagnostics, Alzheimer's Association, RAND, Thomson
Locations:
Geneva, Switzerland, Leqembi, Eisai, Los Angeles, U.S